Clear Search

Showing 2 results for “Rubino DM”.

July 2023

Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Lancet. 2023. DOI: 10.1016/S0140-6736(23)01185-6

Oral semaglutide 7 mg and 14 mg once-daily are approved for the treatment of T2D and improve glycaemic control with accompanying body weight reductions. A higher dose of once-daily oral semaglutide 50 mg is currently being investigated for the treatment of obesity in people with overweight or obesity, and for glycaemic control in people with T2D. The OASIS 1 trial assessed once-daily oral semaglutide 50 mg in adults with overweight or obesity, without T2D.

more…

March 2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

JAMA 2022;327(2):138–50 doi:10.1001/jama.2021.23619

Among adults with overweight or obesity without diabetes, QW SC semaglutide compared with QD SC liraglutide – added to counselling for diet and physical activity – resulted in significantly greater weight loss at 68 weeks.

more…